Warning message
There is currently a suspension or adjustment to some of our activities due to COVID-19. For full details please visit our
Activities in response to COVID-19 information page.
Regulation
The ARPANSA program of work entails six key objectives that guide our priorities and contribute to delivering radiation protection and nuclear safety outcomes to the Australian community.
Performance indicator evidence metrics used for self-assessment 2015-17
On 13 May 2014, the delegate of the CEO of ARPANSA decided to issue a licence to ANSTO to prepare a site for, and construct a controlled facility (the ANSTO SyMo Facility) at the ANSTO Lucas Heights Science and Technology Centre
On 27 June 2014, the CEO of ARPANSA issued a licence to ANSTO to construct a controlled facility (the ANSTO ANM Facility) at the ANSTO Lucas Heights Science and Technology Centre.
Information on major facilities that have been decommissioned or are no longer operating.
An archive of ARPANSA public consultations.
ANM Mo99 facility operating licence application - invitation to make submissions on ANSTO's application for a facility licence.
The following guides have been developed to assist both applicants and licence holders achieve and maintain compliance with the Australian Radiation Protection and Nuclear Safety Act 1998 (the Act)
The Australian Nuclear Medicine Molydenum-99 Facility (ANM Mo99) will be a purpose built radiopharmaceuticals production facility at the ANSTO Lucas Heights site in Sydney. This facility will ensure supplies of Mo-99 for the Australian market and will also have the capacity to export Mo-99 to help secure the future global supply.
Pages
